Cargando…

Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma

Cuproptosis is a novel type of copper-induced cell death and is considered as a new therapeutic target for many cancers. Distant metastases occur in about 40% of patients with advanced renal cell carcinoma (RCC), with a poor 5-year prognosis of about 10%. Through a series of comprehensive analyses,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Jiefu, Yao, Fan, Yao, Zhiyong, Xing, Xiao-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564438/
https://www.ncbi.nlm.nih.gov/pubmed/37728407
http://dx.doi.org/10.18632/aging.205043
_version_ 1785118499016802304
author Tang, Jiefu
Yao, Fan
Yao, Zhiyong
Xing, Xiao-Liang
author_facet Tang, Jiefu
Yao, Fan
Yao, Zhiyong
Xing, Xiao-Liang
author_sort Tang, Jiefu
collection PubMed
description Cuproptosis is a novel type of copper-induced cell death and is considered as a new therapeutic target for many cancers. Distant metastases occur in about 40% of patients with advanced renal cell carcinoma (RCC), with a poor 5-year prognosis of about 10%. Through a series of comprehensive analyses, four differentially expressed cuproptosis-related lncRNAs (DECRLs) were identified as candidate biomarkers for RCC. The risk model constructed by using these four DECRLs can better predict the prognosis of patients with RCC, which is determined by the receiver operating characteristic (Time dependent area under curve value at 1-year, 3-year, 5-year, and 10-year were 0.82, 0.80, 0.76, and 0.73 respectively). There were significant differences in immune status between high-risk and low-risk RCC patients. The differentially expressed gene enrichment terms between high- and low-risk patients was also dominated by immune-related terms. The risk score was also correlated with immunotherapy as measured by the tumor immune dysfunction and exclusion (TIDE) score. In addition, we also found that the sensitivity of many chemotherapy drugs varies widely between high- and low-risk patients. The sensitivity of the three chemotherapy drugs (AZD4547, Vincristine, and WEHI-539) varied among high- and low-risk patients, and was significantly negatively correlated with risk values, suggesting that they could be used as clinical treatment drugs for RCC. Our study not only obtained four potential biomarkers, but also provided guidance for immunotherapy and chemotherapy treatment of RCC, as well as new research strategies for the screening of other cancer biomarkers and sensitive drugs.
format Online
Article
Text
id pubmed-10564438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-105644382023-10-11 Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma Tang, Jiefu Yao, Fan Yao, Zhiyong Xing, Xiao-Liang Aging (Albany NY) Research Paper Cuproptosis is a novel type of copper-induced cell death and is considered as a new therapeutic target for many cancers. Distant metastases occur in about 40% of patients with advanced renal cell carcinoma (RCC), with a poor 5-year prognosis of about 10%. Through a series of comprehensive analyses, four differentially expressed cuproptosis-related lncRNAs (DECRLs) were identified as candidate biomarkers for RCC. The risk model constructed by using these four DECRLs can better predict the prognosis of patients with RCC, which is determined by the receiver operating characteristic (Time dependent area under curve value at 1-year, 3-year, 5-year, and 10-year were 0.82, 0.80, 0.76, and 0.73 respectively). There were significant differences in immune status between high-risk and low-risk RCC patients. The differentially expressed gene enrichment terms between high- and low-risk patients was also dominated by immune-related terms. The risk score was also correlated with immunotherapy as measured by the tumor immune dysfunction and exclusion (TIDE) score. In addition, we also found that the sensitivity of many chemotherapy drugs varies widely between high- and low-risk patients. The sensitivity of the three chemotherapy drugs (AZD4547, Vincristine, and WEHI-539) varied among high- and low-risk patients, and was significantly negatively correlated with risk values, suggesting that they could be used as clinical treatment drugs for RCC. Our study not only obtained four potential biomarkers, but also provided guidance for immunotherapy and chemotherapy treatment of RCC, as well as new research strategies for the screening of other cancer biomarkers and sensitive drugs. Impact Journals 2023-09-19 /pmc/articles/PMC10564438/ /pubmed/37728407 http://dx.doi.org/10.18632/aging.205043 Text en Copyright: © 2023 Tang et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Tang, Jiefu
Yao, Fan
Yao, Zhiyong
Xing, Xiao-Liang
Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
title Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
title_full Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
title_fullStr Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
title_full_unstemmed Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
title_short Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
title_sort characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564438/
https://www.ncbi.nlm.nih.gov/pubmed/37728407
http://dx.doi.org/10.18632/aging.205043
work_keys_str_mv AT tangjiefu characterizationoftumormicroenvironmentandsensitivechemotherapydrugsbasedoncuproptosisrelatedsignaturesinrenalcellcarcinoma
AT yaofan characterizationoftumormicroenvironmentandsensitivechemotherapydrugsbasedoncuproptosisrelatedsignaturesinrenalcellcarcinoma
AT yaozhiyong characterizationoftumormicroenvironmentandsensitivechemotherapydrugsbasedoncuproptosisrelatedsignaturesinrenalcellcarcinoma
AT xingxiaoliang characterizationoftumormicroenvironmentandsensitivechemotherapydrugsbasedoncuproptosisrelatedsignaturesinrenalcellcarcinoma